THMO thermogenesis.com: מכפיל P/S עתידי

ThermoGenesis is recognized as the global benchmark in the field of stem cell cryopreservation. The forward P/S valuation history clearly demonstrates the dynamics of market expectations, while the 0.10 metric confirms the current valuation level. Stable cash flow is driven by the sale of consumables, and management's transformation toward CDMO services creates potential for future revenue growth.

Investors utilize asset filtering based on forward multiples to identify undervalued companies with sustainable growth potential. The forward P/S ratio compares current market capitalization with expected sales volume, which for ThermoGenesis (THMO) allows for an assessment of the business's market value relative to the adoption rates of stem cell processing automation systems, reflecting the scaling efficiency of robotic solutions through the price action on this chart.